Celltrion's COVID-19 Vaccine Phase 2 Clinical Trial Completed, Shares Rise Over 6%

[Asia Economy Reporter Koh Hyung-kwang] Celltrion is showing a sharp rise in the early trading session following news that it has completed the global Phase 2 clinical trial of its COVID-19 antibody treatment.

According to the Korea Exchange on the 25th, as of 10:54 AM, Celltrion was trading at 321,000 KRW on the KOSPI market, up 6.4% from the previous trading day. The stock price appears to be rising after Celltrion announced the completion of recruitment and dosing of 327 subjects for the global Phase 2 clinical trial of its COVID-19 antibody treatment 'CT-P59'. Celltrion plans to apply for conditional approval from the Ministry of Food and Drug Safety once the interim results of the Phase 2 trial are available.

Celltrion also plans to start the global Phase 3 clinical trial of CT-P59 in more than 10 countries worldwide. The company intends to accelerate the final product approval process for CT-P59 by following clinical procedures that comply with the new drug approval regulations of regulatory agencies worldwide. Furthermore, Celltrion plans to produce up to 1.5 to 2 million treatment doses annually for large-scale overseas supply in the future.